Citations

Clear

3314 citation(s) found for "Do, Alexander".

Phase I dose escalation trial of the first-in-class TNFR2 agonist monoclonal antibody, HFB200301, in monotherapy and in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in adult patients with advanced solid tumors.
Roda, Desamparados , Zugazagoitia, Jon , Oppelt, Peter John, Lin, Xi , Xie, Shaozhen, Chen, Margaret E, Wong, Gabrielle, Pollard, Jack Russella, Hedrich, William D. , Pallante, John, Hatzis, Christos, Andtbacka, Robert H.I. , Garralda, Elena , Spira, Alexander I. , El-Khoueiry, Anthony B. , Babiker, Hani M. , Oppelt, Peter John, Gan, Jinping

Mayo Clinic

Journal of Clinical Oncology | June 17, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 2526-2526

10.1200/jco.2024.42.16_suppl.2526 Get It

2526 Background: Tumor necrosis factor receptor-2 (TNFR2) is expressed on effector CD8+, CD4+, and regulatory T (Treg) cells, natural killer (NK) cells, and myeloid cells. Activation of TNFR2 is anticipated to yield effective anti-tumor immunity by stimulating T-cell and NK-cell activation and proliferation in the tumor microenvironment. HFB200301 is a first-in-class anti-TNFR2 agonistic monoclonal antibody that triggers both innate and adaptive immune stimulation by binding to a specific epitope on TNFR2. We report initial results of an ongoing Phase I dose escalation, multicenter study (NCT05238883) of HFB200301 in monotherapy and in combination with tislelizumab (TIS) in patients (pts) with advanced refractory solid tumors. Methods: A Phase I trial designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and initial efficacy of HFB200301 in monotherapy and in combination with TIS. Eligible pts, ≥18 years with an ECOG PS 0-1 and advanced solid tumors, will be enrolled in dose escalation at 5 different dose cohorts in monotherapy (Q4W), 3 different dose cohorts in combination with TIS (Q4W), or in dose expansion following determination of safety. Radiographic response is assessed every 8 weeks. Results: A total of 39 pts have been enrolled, 27 pts in monotherapy and 12 pts in combination. All pts received prior systemic therapy (median 2, range 1-4); 23 pts (59%) had prior checkpoint inhibitor treatment. No dose limiting toxicities were observed in either the monotherapy or combination arms. Treatment-related adverse events (TRAEs) occurred in 44% of monotherapy and in 50% of combination pts, with pruritis (11%), tremor (7%), fatigue (7%), asthenia (7%) and nausea (7%) being the most common TRAEs. No ≥ Grade 3 TRAEs were reported, and there were no drug discontinuations due to TRAEs. Preliminary HFB200301 PK analysis demonstrated non-linear clearance of HFB200301, with dose-proportional maximum concentration [Cmax], achieving sufficient exposures for peripheral target engagement in all tested doses. Emerging PD data demonstrates evidence of immune activation and expansion of CD8+ T cells, but not Tregs, in the tumor microenvironment and peripheral blood. Single cell RNAseq analysis of peripheral blood mononuclear cells demonstrated PD modulation in TNFR2 positive immune cell types post-HFB200301 treatment. Early response evaluation reveals ongoing durable clinical responses (> 6 months) in a PD-L1+ pleural mesothelioma pt and an EBV+ gastric cancer pt from combination cohorts. Conclusions: HFB200301 demonstrates a favorable safety profile, dose-dependent PK, with PD and preliminary clinical activity in monotherapy and in combination with TIS in pts with heavily pre-treated refractory solid tumors. Clinical trial information: NCT05238883 .
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
Etra, Aaron , Jurdi, Najla El , Katsivelos, Nikolaos , Gergoudis, Stephanie, Morales, George , Spyrou, Nikolaos , Kowalyk, Steven, Aguayo‐Hiraldo, Paibel , Akahoshi, Yu , Ayuk, Francis, Baez, Janna , Chanswangphuwana, Chantiya , Chen, Yi‐Bin , Choe, Hannah , DeFilipp, Zachariah , Gleich, Sigrun, Holler, Ernst , MacMillan, Margaret L. , Pawarode, Attaphol , Quagliarella, Francesco , Schechter, Tal , Vášová, Ingrid, Wölfl, Matthias , Young, Rachel , Nakamura, Ryotaro , Ferrara, James L.M. , El Jurdi, Najla , Spyrou, Nikolaos , Aguayo-Hiraldo, Paibel , Chen, Yi-Bin , DeFilipp, Zachariah , Hexner, Elizabeth , Hogan, William J , Al Malki, Monzr M , Quagliarella, Francesco , Qayed, Muna , Weisdorf, Dan , Wölfl, Matthias , Nakamura, Ryotaro , Levine, John E , Holtan, Shernan , Katsivelos, Nikolaos , Akahoshi, Yu , Kwon, Deukwoo , Betts, Brian Christopher , Hexner, Elizabeth O. , Hogan, William J. , Kitko, Carrie L. , Kraus, Sabrina , Malki, Monzr M. Al , Reshef, Ran , Weisdorf, Daniel J. , Levine, John E. , Holtan, Shernan G.

Mayo Clinic

Blood Advances | June 14, 2024 | Volume: 8 | Issue: 12 | Pages: 3284-3292

10.1182/bloodadvances.2023011049 | PMID 38640195 Get It

Abstract Graft-versus-host disease (GVHD) is a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Algorithms containing either the gastrointestinal (GI) GVHD biomarker amphiregulin (AREG) or a combination of 2 GI GVHD biomarkers (suppressor of tumorigenicity-2 [ST2] + regenerating family member 3 alpha [REG3α]) when measured at GVHD diagnosis are validated predictors of NRM risk but have never been assessed in the same patients using identical statistical methods. We measured the serum concentrations of ST2, REG3α, and AREG by enzyme-linked immunosorbent assay at the time of GVHD diagnosis in 715 patients divided by the date of transplantation into training (2004-2015) and validation (2015-2017) cohorts. The training cohort (n = 341) was used to develop algorithms for predicting the probability of 12-month NRM that contained all possible combinations of 1 to 3 biomarkers and a threshold corresponding to the concordance probability was used to stratify patients for the risk of NRM. Algorithms were compared with each other based on several metrics, including the area under the receiver operating characteristics curve, proportion of patients correctly classified, sensitivity, and specificity using only the validation cohort (n = 374). All algorithms were strong discriminators of 12-month NRM, whether or not patients were systemically treated (n = 321). An algorithm containing only ST2 + REG3α had the highest area under the receiver operating characteristics curve (0.757), correctly classified the most patients (75%), and more accurately risk-stratified those who developed Minnesota standard-risk GVHD and for patients who received posttransplant cyclophosphamide-based prophylaxis. An algorithm containing only AREG more accurately risk-stratified patients with Minnesota high-risk GVHD. Combining ST2, REG3α, and AREG into a single algorithm did not improve performance.
Statin use does not impact sentinel lymph node metastasis and recurrence in melanoma patients: an 844‐patient retrospective study
Jing, Frank Z. , Pazhava, Ani , Meves, Alexander , Yu, Wesley Y. , Meves, Alexander , Yu, Wesley Y , Jing, Frank Z , Todd, Austin W.

Mayo Clinic

International Journal of Dermatology | June 13, 2024 | Volume: 64 | Issue: 1 | Pages: 178-179

10.1111/ijd.17320 | PMID 38867411 Get It

Creating elastase aneurysms in rabbits: a video primer
Cortese, Jonathan , Bayraktar, Esref Alperen , Oliver, Alexander A , Bilgin, Cem , Ding, Yong-Hong, Ueki, Yasuhito , Lortscher, Sarah, Brinjikji, Waleed , Kadirvel, Ramanathan , Kallmes, David F. , Cortese, Jonathan , Bayraktar, Esref Alperen , Oliver, Alexander A , Ding, Yonghong

Mayo Clinic

Journal of NeuroInterventional Surgery | June 11, 2024 | Volume: 17 | Issue: 10 | Pages: 1133-1133

10.1136/jnis-2024-021912 | PMID 38862208 Get It

The New Zealand rabbit elastase-induced arterial aneurysm of the right common carotid artery remains a widely used model for assessing the effectiveness and safety of new neuroendovascular devices.1 This model offers a simple and reliable platform for pre-clinical in vivo investigations, crucial for comprehending the biological processes underlying aneurysm healing after endovascular treatment.2 Notably, the induced aneurysm exhibits morphological, hemodynamic, and histological characteristics similar to human intracranial aneurysms. The creation of the aneurysm is performed using open and endovascular techniques. Each step of the procedure requires a meticulous and controlled gesture to ensure reproducibility of the aneurysm and minimize animal misuse. In video 1 we present a step-by-step procedural guide for aneurysm creation and follow-up. We hope this resource will help in promoting this model and provide useful guidance for researchers in the field. Video 1 Surgical procedure of creating elastase-induced aneurysms in rabbits.
Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Ahsan, Aarif, Mantis, Christine, Luo, Xizhi, Zhang, Catherine, Valdes, Cesar Rodriguez , Voorhees, Peter M. , Safah, Hana, McKay, John T., Korde, Neha , Vij, Ravi , Kumar, Shaji , Bueno, Orlando Felix, Pothacamury, Rajvineeth Kumar, D’Souza, Anita , Chung, Alfred , Tuchman, Sascha Alexander , McKay, John, Weisel, Katja C , Teipel, Raphael , Bueno, Orlando F. , Talati, Chetasi , Ross, Jeremy A.

Mayo Clinic

Journal of Clinical Oncology | June 10, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 7532-7532

10.1200/jco.2024.42.16_suppl.7532 Get It

7532 Background: ABBV-383 is a BCMA x CD3 bispecific antibody with 2 high-affinity BCMA-binding domains and a low-affinity CD3 engaging arm that has been shown to decrease the negative impact of soluble BCMA (sBCMA) and drive sustained T-cell activation with reduced cytokine release in preclinical models of MM. Here, we describe correlative biomarker results of baseline and longitudinal sBCMA levels and immune profiles in the ongoing first-in-human trial that supports 60 mg Q4W as the optimal therapeutic dose of ABBV-383 monotherapy. Methods: Peripheral blood and serum samples from patients with RRMM enrolled in the phase 1 open-label, dose-expansion study (NCT03933735) who received ABBV-383 at 20, 40, or 60 mg Q3W or 60 mg Q4W were collected at baseline (post-dexamethasone, pre–ABBV-383), on treatment, and at disease progression. Samples were analyzed by flow cytometry for immune cell populations, Luminex for cytokines, and electrochemiluminescence ligand binding for sBCMA. Results: Median sBCMA levels at baseline were highly variable among patients, but did not associate with clinical response (≥ partial response [PR]) to ABBV-383 at the selected optimal dose level of 60 mg Q4W (<PR: 244.7 ng/mL; ≥PR: 52.2 ng/mL; P=0.13). Reduction in sBCMA levels over time associated with clinical response (Cmin at cycle 5: <PR, 244.7 ng/mL; ≥PR, 4.7 ng/mL; P=0.04). ABBV-383 treatment led to a rapid and transient increase of proinflammatory cytokines, including IL-6, IL-8, IL-10, TNF-α (Cmax within cycle 1: 29, 349.5, 1375, 456.5 pg/mL, respectively), and promoted T-cell redistribution (89% reduction of CD8+ T cells from periphery), activation (1.9-fold increase in CD69+CD8+ T cells), and proliferation (2-fold increase in Ki67+CD8+ T cells) within cycle 1 in 60-mg Q4W-treated patients. The frequency of baseline CD8+ T-cell exhaustion (PD-1/TIM3) did not impact clinical response at the optimal dose level of 60 mg Q4W ABBV-383 (<PR: 3.5%; ≥PR: 3.9%; P=0.9). Peak induction levels of proinflammatory cytokines during cycle 1 correlated with occurrence of cytokine release syndrome (≥G1) as well as clinical response across dose levels. Conclusions: High-avidity BCMA binding coupled to low-affinity T-cell engagement distinguishes the resulting mechanism of action for ABBV-383. Responses to 60 mg Q4W ABBV-383 were independent of baseline sBCMA levels and resulted in rapid and transient proinflammatory cytokine production that promoted robust T-cell redistribution, activation, and proliferation, indicating that the optimal dose of ABBV-383 maximizes its clinical potential as a convenient, safe, and effective therapy for MM. Clinical trial information: NCT03933735 .
Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
Valdes, Cesar Rodriguez , Voorhees, Peter M. , Safah, Hana, McKay, John T., Korde, Neha , Vij, Ravi, Bueno, Orlando Felix, Rosenberg, Tanya, Pothacamury, Rajvineeth Kumar, Polepally, Akshanth, Ahsan, Aarif, Kumar, Shaji , D’Souza, Anita , Chung, Alfred , Tuchman, Sascha Alexander , McKay, John, Weisel, Katja C , Teipel, Raphael , Bueno, Orlando F. , (Lee), Xin (Shane) Li, Jin, Ziyi , Talati, Chetasi

Mayo Clinic

Journal of Clinical Oncology | June 10, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 7531-7531

10.1200/jco.2024.42.16_suppl.7531 Get It

7531 Background: MM eventually becomes refractory to current treatments, and new therapeutic options with convenient dosing and improved safety are needed to enhance patient (pt) adherence, access, and outcomes. ABBV-383 is a distinctive next-generation BCMA x CD3 bispecific antibody composed of 2 high-affinity BCMA-binding domains, a low-affinity CD3-binding domain designed to reduce cytokine release syndrome (CRS) risk, and a silenced Fc tail for an extended half-life allowing convenient dosing. ABBV-383 monotherapy has shown promising activity in the ongoing first-in-human phase 1 trial in RRMM (Vij et al. Blood 2023;142[suppl 1]:3378). Here, safety and efficacy results are reported that support the RP2D of 60mg Q4W as the optimal therapeutic ABBV-383 monotherapy dose. Methods: This phase 1 open-label, dose-escalation/expansion trial (NCT03933735) enrolled pts with RRMM who received ≥3 prior lines of therapy with exposure to PI, IMiD, and anti-CD38 mAb. ABBV-383 regimens explored in the expansion phase included 60mg Q4W and 40 or 60mg Q3W. A modified dexamethasone premedication schedule and shortened CRS monitoring period were implemented in the 60mg Q4W cohort for cycle 1. IV ABBV-383 was administered as a flat dose with no step-up schedule. Treatment was continued until disease progression/unacceptable toxicity. Primary objectives were to assess safety, tolerability, PK, PD, and determine the RP2D. Efficacy evaluation was a secondary objective. TEAEs were assessed per CTCAE v5.0 and tumor response per IMWG 2016 criteria. Results: As of May 2023, 220 pts received ABBV-383 (median age: 68 yr [35–92]; median prior therapy lines: 5 [3‒23]). Median FU was 4.1 mo (0.8–5.2) at 60mg Q4W (n=21), 12.2 mo (1.3–34.4) at 40mg Q3W (n=55), and 24.2 mo (0.6–33.4) at 60mg Q3W (n=61). At 60mg Q4W, with the modified premedication regimen, CRS was reported in 43% of pts (38% G1, 5% G2), and ICANS in 5% of pts (G2). In Q3W cohorts, CRS was reported in 71% (40mg; 45% G1, 25% G2) and 70% (60mg; 51% G1, 18% G2, 2% G3) of pts. The incidence of G3/4 neutropenia, anemia, and thrombocytopenia was 14/24/10% at 60mg Q4W, 31/31/16% at 40mg Q3W, and 34/13/13% at 60mg Q3W. G3/4 infections occurred in 10/24/34% of pts at 60mg Q4W, 40mg and 60mg Q3W, respectively. ORR and ≥VGPR were 65/50% at 60mg Q4W, 64/53% at 40mg Q3W, and 60/52% at 60mg Q3W. Corresponding exposure-response (ER) analyses and correlative analyses further supported RP2D determination (separate abstract submissions). Conclusions: The optimal therapeutic dose of 60mg Q4W ABBV-383 monotherapy was selected on the basis of safety, efficacy, and ER analyses. The extended interval of Q4W, with a shortened CRS monitoring period in cycle 1 and no step-up dosing, will improve convenience and reduce the treatment burden for pts. ABBV-383 at 60mg Q4W will be investigated in the registrational phase 3 trial (NCT06158841) in RRMM. Clinical trial information: NCT03933735 .
Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9.
Sborov, Douglas W. , Ishida, Tadao, Huang, Jeffrey, Iida, Shinsuke , Popat, Rakesh , Pianko, Matthew J. , Ramakrishnan, Aravind , Dabak, Vrushali, Conte, Umberto, Soltantabar, Pooneh , Vandendries, Erik, Pawlyn, Charlotte , Ishida, Tadao , Benjamin, Reuben , Popat, Rakesh , Kuroda, Junya , Schuster, Steven Robert , Lesokhin, Alexander M. , Soltantabar, Pooneh , Hong, Fangxin , Fonseca, Rafaël

Mayo Clinic

Journal of Clinical Oncology | June 10, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 7522-7522

10.1200/jco.2024.42.16_suppl.7522 Get It

7522 Background: Elranatamab (ELRA) is a humanized BCMA-CD3 bispecific antibody. In the phase 2 registrational MagnetisMM-3 (MM-3) trial, SC ELRA was given as 2 step-up priming doses (12 mg on C1D1 and 32 mg on C1D4) followed by 76 mg QW in patients (pts) with RRMM. Overall, 56.3% of pts had CRS (grade 2, 14.3%; no grade ≥3). Most events occurred after doses 1 (44.5%), 2 (20.2%), and 3 (5.9%); 0.8% (1 pt) had CRS with doses 4+. Recurrent CRS (>1 event) occurred in 15.1% of pts (Lesokhin Nat Med 2023). Methods: MagnetisMM-9 (MM-9; NCT05014412) is a phase 1/2, open-label, nonrandomized study of ELRA examining an alternative 2-dose step-up priming regimen (4 and 20 mg on C1D1 and C1D4, respectively). Eligible pts had RRMM and were refractory to ≥1 IMiD, ≥1 PI, and ≥1 anti-CD38 antibody. After the priming doses, ELRA 76 mg was given QW for 6 cycles (Part 1) or for 1 cycle followed by 116 or 152 mg Q2W for 5 cycles (Part 2A). The RP2D from Part 2A (152 mg) was evaluated in Part 2B (dose expansion). The rate of grade ≥2 CRS per ASTCT criteria during C1 is the primary endpoint for both parts. Secondary endpoints include evaluation of AEs and PK. Here, we report the overall safety and CRS profile associated with the 4/20 mg priming regimen. Results: For 85 treated pts, median age was 64.0 y; 49.4% were male; 23.5% had EMD; 31.8% had high-risk cytogenetics. Pts had a median of 5.0 (range, 1-12) prior LOTs; 85.9% had triple-class refractory disease. After a median follow-up of 7.4 mo, the most common (>50%) AEs were CRS (63.5%; grade ≥2, 15.3%) and neutropenia (54.1%; all grade ≥2). ICANS occurred in 4.7% of pts (all grade ≤2). The grade ≥2 CRS rate in C1 was 14.1% (90% CI, 8.4-21.9). CRS rates after the first 3 doses are in the the table. For doses 4+, any grade (grade ≥2) CRS was observed in 10.6% (3.5%) of pts overall, 12.1% (3.0%) of pts continuing to receive 76 mg (n=33), 25.0% (0%) of pts receiving 116 mg (n=12), and 5.0% (5.0%) of pts receiving 152 mg (RP2D; n=40). Overall, recurrent CRS was observed in 20.0% of pts. The geometric means (CV%) of free ELRA concentrations 24 h (Cmax-24h) after step-up doses 1 and 2 were 85.64 (48%) and 242.8 (55%). Conclusions: The 4/20 mg step-up priming regimen and alternative dosing schedules resulted in similar safety and incidence of overall and grade ≥2 CRS events vs the regimen used in MM-3 (12/32 mg), with no new safety signals identified. However, the CRS profile in this study differed, with more CRS after doses 2, 3, and 4+ and a higher prevalence of recurrent CRS. The Cmax-24h of free ELRA (CV%) after the priming doses were lower than those in MM-3 (107.4 [47%] and 405.1 [72%], respectively). Thus, the priming regimen used in MM-3 remains the optimal regimen for mitigating CRS. Future analyses of ongoing studies will be used to confirm these results. Clinical trial information: NCT05014412 . [Table: see text]
Phase III randomized trial of intensity-modulated proton therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for the treatment of head and neck oropharyngeal carcinoma (OPC).
Busse, Paul M., Gunn, Gary Brandon, Patel, Samir H. , LEE, NANCY Y., Lin, Alexander , Snider, J.W. , Bajaj, Gopal , Kalman, Noah S. , Katz, Sanford , Foote, Robert L. , Frank, Steven J. , Rosenthal, David I. , Hernández, Mike , Swanson, David Michael , Garden, Adam S. , Sturgis, Erich M. , Ferrarotto, Renata , Gunn, Gary Brandon, McDonald, Mark William , Henson, Christina , Parvathaneni, Upendra

Mayo Clinic

Journal of Clinical Oncology | June 10, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 6006-6006

10.1200/jco.2024.42.16_suppl.6006 Get It

6006 Background: IMPT has unique biologic and physical properties compared with IMRT, limits radiation dose beyond the targeted tumor volumes, and is a novel de-intensification strategy for the management of head and neck tumors. This study was designed to compare the outcomes for patients with OPC after chemoradiation therapy (CRT) with IMRT vs IMPT. Methods: This is a multi-center, randomized, phase III non-inferiority OPC trial Stage III/IV (AJCC 7th) squamous cell carcinoma stratified patients by human papillomavirus status, smoking status, and receipt of induction chemotherapy (IC). The primary endpoint was the rate of progression-free survival (PFS) rate at 3 years, where progression was defined as disease recurrence or death. Under the null hypothesis, H0: r ≥ 1.535 established the margin for non-inferiority of IMPT. Secondary endpoints include overall survival (OS), treatment-related malnutrition, and gastrostomy-tube dependence. Analyses were conducted on intent-to-treat (ITT; n=440), per-protocol (PP; n=296), and as-treated (AT; n=397) populations. Results: Patients (n=440) were randomized to undergo IMRT(n=219) or IMPT (n=221) at 21 institutions. The median age was 61 years and HPV/p16 was positive in 95%. IC was the initial treatment in 13% of patients. All patients were treated with CRT to 70 Gy in 33 fx with bilateral neck treatment, and post-CRT surgical lymph node dissection occurred in 8%. The median follow-up was 3.14 years. In the ITT analysis, the hazard ratio (HR) for disease progression or death at 3 y was 0.87 (95%CI 0.56,1.35); p=0.006 and the corresponding HR for death (OS) was 0.63 (95%CI 0.36-1.10) suggesting a protective affect with IMPT. In PP analysis, the PFS HR was 0.85 (95%CI 0.52,1.38); p=0.009 and HR for death (OS) was 0.60 (95%CI 0.32-1.12). In the AT analysis, PFS HR was 0.88 (95%CI 0.56,1.37); p=0.007 and the corresponding HR for death (OS) was 0.70 (95%CI 0.40-1.22). For each analysis above, the null hypothesis was rejected and IMPT was non-inferior to IMRT. PP gastrostomy-tube dependence decreased with IMPT vs. IMRT from 42% to 28% (p=0.019), and more IMPT patients sustained their nutrition with end of treatment weight loss < 5% from baseline: 24% vs 14% (p=0.037). Conclusions: IMPT is non-inferior to IMRT and has emerged as a standard of care CRT approach for OPC that reduces malnutrition and gastrostomy-tube dependence. Clinical trial information: NCT01893307 .
Education in cardio-oncology: the next frontiers
Farmakis, Dimitrios , Hermann, Joerg, López‐Fernández, Teresa , Herrmann, Joerg , López-Fernández, Teresa , Lyon, Alexander R.

Mayo Clinic

European Heart Journal | June 7, 2024 | Volume: 45 | Issue: 27 | Pages: 2352-2354

10.1093/eurheartj/ehad895 | PMID 38845152 Get It

Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Saner, Flurina A.M. , Takahashi, Kazuaki , Budden, Timothy , Pandey, Ahwan , Ariyaratne, Dinuka , Zwimpfer, Tibor A. , Meagher, Nicola S. , Twomey, Laura , Hoang, Therese, Group, for the Australian Ovarian Cancer Study, Christie, Elizabeth L. , Kang, Eun-Young , Nelson, Gregg , Riggan, Marjorie J. , Alsop, Jennifer , Beckmann, Matthias W. , Boros, Jessica , Brand, Alison H. , Carney, Michael E. , Coulson, Penny , Courtney‐Brooks, Madeleine , Cushing‐Haugen, Kara L. , El‐Bahrawy, Mona , Gayther, Simon A. , Hartmann, Arndt , Hendley, Joy , Jimenez-Linan, Mercedes , Jones, Michael E. , Kluz, Tomasz , Koziak, Jennifer M. , Kristjansdottir, Björg , Le, Nhu D. , Lener, Marcin , Lester, Jenny , Mateoiu, Constantina , Oršulić, Sandra , Ruebner, Matthias , Schoemaker, Minouk J. , Shah, Mitul , Sharma, Raghwa , Shvetsov, Yurii B. , Soong, T. Rinda , Sukumvanich, Paniti , Talhouk, Aline , Anglesio, Michael S. , Fasching, Peter A. , Goodman, Marc T. , Huntsman, David G. , Kelemen, Linda E. , Menon, Usha , Pharoah, Paul D.P. , Schildkraut, Joellen M. , Goode, Ellen L. , Ramus, Susan J. , Bowtell, David D.L. , Garsed, Dale W. , Fereday, Sian , Twomey, Laura , Pishas, Kathleen I , Hoang, Therese , Bolithon, Adelyn , Traficante, Nadia , Alsop, Kathryn , Christie, Elizabeth L , Kang, Eun-Young , Nelson, Gregg S , Ghatage, Prafull , Lee, Cheng-Han , Riggan, Marjorie J , Alsop, Jennifer , Beckmann, Matthias W. , Boros, Jessica , Brand, Alison H , Brooks-Wilson, Angela R , Carney, Michael E , Coulson, Penny , Courtney-Brooks, Madeleine , Cushing-Haugen, Kara L , Cybulski, Cezary , El-Bahrawy, Mona A , Elishaev, Esther , Erber, Ramona , Gayther, Simon A , Gentry‐Maharaj, Aleksandra , Gilks, C. Blake , Harnett, Paul R , Harris, Holly R , Hartmann, Arndt , Hein, Alexander , Hendley, Joy , Hernandez, Brenda Y , Jakubowska, Anna , Jimenez-Linan, Mercedes , Jones, Michael E , Kaufmann, Scott H , Kennedy, Catherine J , Kluz, Tomasz , Koziak, Jennifer M , Kristjansdottir, Björg , Le, Nhu D , Lener, Marcin , Lester, Jenny , Lubinski, Jan , Mateoiu, Constantina , Orsulic, Sandra , Ruebner, Matthias , Schoemaker, Minouk J , Shah, Mitul , Sharma, Raghwa , Sherman, Mark E , Shvetsov, Yurii B , Soong, T Rinda , Steed, Helen , Sukumvanich, Paniti , Talhouk, Aline , Taylor, Sarah E , Vierkant, Robert A , Wang, Chen , Widschwendter, Martin , Wilkens, Lynne R , Winham, Stacey J , Anglesio, Michael S , Berchuck, Andrew , Brenton, James D , Campbell, Ian G , Cook, Linda S. , Doherty, Jennifer A , Fasching, Peter A , Fortner, Renée T , Goodman, Marc T , Gronwald, Jacek , Huntsman, David G , Karlan, Beth Y , Kelemen, Linda E , Menon, Usha , Modugno, Francesmary , Pharoah, Paul D P , Schildkraut, Joellen M , Sundfeldt, Karin , Swerdlow, Anthony J , Goode, Ellen L , Fazio, Anna de , Köbel, Martin , Ramus, Susan J , Bowtell, David D , Garsed, Dale W , Ariyaratne, Dinuka , Pandey, Ahwan , Fereday, Sián , Traficante, Nadia , Group, for the Australian Ovarian Cancer Study, Alsop, Kathryn , Lee, Cheng‐Han , Brooks‐Wilson, Angela , Cybulski, Cezary , Elishaev, Esther , Harnett, Paul R. , Harris, Holly R. , Hein, Alexander , Hernandez, Brenda Y. , Jakubowska, Anna , Kaufmann, Scott H. , Kennedy, Catherine J. , Lubiński, Jan , Sherman, Mark E. , Steed, Helen , Vierkant, Robert A. , Wang, Chen , Widschwendter, Martin , Wilkens, Lynne R. , Winham, Stacey J. , Berchuck, Andrew , Brenton, James D. , Campbell, Ian , Doherty, Jennifer A. , Fortner, Renée T. , Gronwald, Jacek , Karlan, Beth Y. , Modugno, Francesmary , Swerdlow, Anthony J. , DeFazio, Anna , Köbel, Martin

Mayo Clinic

Clinical Cancer Research | June 5, 2024 | Volume: 30 | Issue: 16 | Pages: 3481-3498

10.1158/1078-0432.ccr-23-3552 | PMID 38837893 Get It

Abstract Purpose: The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes and how co-occurrence of BRCA1 or BRCA2 (BRCA) alterations and RB1 loss influences survival in tubo-ovarian high-grade serous carcinoma (HGSC). Experimental Design: RB1 protein expression was classified by immunohistochemistry in ovarian carcinomas of 7,436 patients from the Ovarian Tumor Tissue Analysis consortium. We examined RB1 expression and germline BRCA status in a subset of 1,134 HGSC, and related genotype to overall survival (OS), tumor-infiltrating CD8+ lymphocytes, and transcriptomic subtypes. Using CRISPR-Cas9, we deleted RB1 in HGSC cells with and without BRCA1 alterations to model co-loss with treatment response. We performed whole-genome and transcriptome data analyses on 126 patients with primary HGSC to characterize tumors with concurrent BRCA deficiency and RB1 loss. Results: RB1 loss was associated with longer OS in HGSC but with poorer prognosis in endometrioid ovarian carcinoma. Patients with HGSC harboring both RB1 loss and pathogenic germline BRCA variants had superior OS compared with patients with either alteration alone, and their median OS was three times longer than those without pathogenic BRCA variants and retained RB1 expression (9.3 vs. 3.1 years). Enhanced sensitivity to cisplatin and paclitaxel was seen in BRCA1-altered cells with RB1 knockout. Combined RB1 loss and BRCA deficiency correlated with transcriptional markers of enhanced IFN response, cell-cycle deregulation, and reduced epithelial–mesenchymal transition. CD8+ lymphocytes were most prevalent in BRCA-deficient HGSC with co-loss of RB1. Conclusions: Co-occurrence of RB1 loss and BRCA deficiency was associated with exceptionally long survival in patients with HGSC, potentially due to better treatment response and immune stimulation.